Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pediatr Surg ; 52(1): 35-39, 2017 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-27916444

RESUMO

PURPOSE: Neonates after emergent enterostomy creation frequently require reversal at low weight because of complications including cholestasis, dehydration, dumping, failure to thrive, and failure to achieve enteral independence. We investigated whether stoma reversal at low weight (< 2.5kg) is associated with poor surgical outcomes. METHODS: Patients who underwent enterostomy reversal from 2005 to 2013 at less than 6months old were identified in our institutional database. Only patients who underwent emergent enterostomy creation (i.e. for necrotizing enterocolitis or spontaneous perforation) were included. Demographics, disease process, comorbidities, stoma type, reversal indication, operative details, and complications were examined. Patients were categorized by weight at reversal of less than 2kg, 2.01-2.5kg, 2.51-3.5kg, and greater than 3.5kg. Data were analyzed using univariable and multivariable regression with significance level of p<0.05. The primary outcome examined was major morbidity, defined as the presence of anastomotic leak, obstruction, hernia, EC fistula, perforation, wound infection, sepsis, or death. RESULTS: Eighty-nine patients met inclusion criteria. Demographics (sex, ethnicity, surgical disease process, reversal indication, and ASA score) were similar. The lowest weight group had lower gestational age (p<0.001) and birth weight (p=0.005), and contained a higher proportion of jejunostomies to ileostomies (p=0.013). On univariable analysis, only incisional hernia was significantly different as a complication between weight groups. On multivariable analysis controlling for gestational age and ASA, there was no significant difference in odds of major operative morbidity between groups. CONCLUSIONS: Enterostomy reversal at lower weight may not be associated with increased risk of perioperative complications. Early stoma reversal may be acceptable when required for progression of neonatal care. LEVEL OF EVIDENCE: Level III, Treatment Study (Retrospective comparative study).


Assuntos
Peso Corporal , Enterostomia , Reoperação , Estomas Cirúrgicos , Peso ao Nascer , Colestase/etiologia , Enterocolite Necrosante/cirurgia , Enterostomia/efeitos adversos , Feminino , Idade Gestacional , Humanos , Lactente , Recém-Nascido , Perfuração Intestinal/cirurgia , Masculino , Complicações Pós-Operatórias , Estudos Retrospectivos , Resultado do Tratamento
2.
J Urol ; 196(5): 1530-1535, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27259655

RESUMO

PURPOSE: Wilms tumor is the most common childhood renal malignancy and the fourth most common childhood cancer. Many biomarkers have been studied but there has been no comprehensive summary. We systematically reviewed the literature on biomarkers in Wilms tumor to quantify the prognostic implications of the presence of individual tumor markers. MATERIALS AND METHODS: We searched for English language studies from 1980 to 2015 performed in patients younger than 18 years with Wilms tumor and prognostic data. The protocol was conducted per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Two reviewers abstracted data in duplicate using a standard evaluation form. We performed descriptive statistics, then calculated relative risks and 95% confidence intervals for markers appearing in multiple level II or III studies. RESULTS: A total of 40 studies were included examining 32 biomarkers in 7,381 patients with Wilms tumor. Studies had a median of 61 patients, 24 biomarker positive patients per series and a median followup of 68.4 months. Median percentages of patients with stages 1, 2, 3, 4 and 5 tumors were 28.5%, 26.4%, 24.5%, 14.1% and 1.7%, respectively, and 10.2% had anaplasia. The strongest negative prognostic association was loss of heterozygosity at 11p15, with a risk of recurrence of 5.00, although loss of heterozygosity at 1p and gain of function at 1q were also strongly linked to increased recurrence (2.93 and 2.86, respectively). CONCLUSIONS: Several tumor markers are associated with an increased risk of recurrence or a decreased risk of overall survival in patients with Wilms tumor. These data suggest targets for development of diagnostic tests and potential therapies.


Assuntos
Neoplasias Renais/diagnóstico , Tumor de Wilms/diagnóstico , Biomarcadores Tumorais/sangue , Criança , Humanos , Neoplasias Renais/sangue , Prognóstico , Tumor de Wilms/sangue
3.
Pediatr Blood Cancer ; 62(9): 1495-500, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25807938

RESUMO

Analysis of data from large administrative databases and patient registries is increasingly being used to study childhood cancer care, although the value of these data sources remains unclear to many clinicians. Interpretation of large databases requires a thorough understanding of how the dataset was designed, how data were collected, and how to assess data quality. This review will detail the role of administrative databases and registry databases for the study of childhood cancer, tools to maximize information from these datasets, and recommendations to improve the use of these databases for the study of pediatric oncology.


Assuntos
Mineração de Dados , Bases de Dados Factuais , Oncologia , Neoplasias/epidemiologia , Pediatria , Sistema de Registros , American Cancer Society , Cirurgia Geral , Custos de Cuidados de Saúde/estatística & dados numéricos , Sistemas de Informação em Saúde , Humanos , Pacientes Internados/estatística & dados numéricos , Seguradoras , Medicaid , Neoplasias/economia , Neoplasias/terapia , Admissão do Paciente/estatística & dados numéricos , Alta do Paciente/estatística & dados numéricos , Programa de SEER , Sociedades Médicas , Software , Resultado do Tratamento , Estados Unidos , United States Agency for Healthcare Research and Quality
4.
Dev Neurosci ; 37(4-5): 349-62, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25791742

RESUMO

Cerebral palsy (CP) has a significant impact on both patients and society, but therapy is limited. Human umbilical cord blood cells (HUCBC), containing various stem and progenitor cells, have been used to treat various brain genetic conditions. In small animal experiments, HUCBC have improved outcomes after hypoxic-ischemic (HI) injury. Clinical trials using HUCBC are underway, testing feasibility, safety and efficacy for neonatal injury as well as CP. We tested HUCBC therapy in a validated rabbit model of CP after acute changes secondary to HI injury had subsided. Following uterine ischemia at 70% gestation, we infused HUCBC into newborn rabbit kits with either mild or severe neurobehavioral changes. Infusion of high-dose HUCBC (5 × 10(6) cells) dramatically altered the natural history of the injury, alleviating the abnormal phenotype including posture, righting reflex, locomotion, tone, and dystonia. Half the high dose showed lesser but still significant improvement. The swimming test, however, showed that joint function did not restore to naïve control function in either group. Tracing HUCBC with either MRI biomarkers or PCR for human DNA found little penetration of HUCBC in the newborn brain in the immediate newborn period, suggesting that the beneficial effects were not due to cellular integration or direct proliferative effects but rather to paracrine signaling. This is the first study to show that HUCBC improve motor performance in a dose-dependent manner, perhaps by improving compensatory repair processes.


Assuntos
Paralisia Cerebral/terapia , Transplante de Células-Tronco de Sangue do Cordão Umbilical/métodos , Hipóxia-Isquemia Encefálica/complicações , Atividade Motora/fisiologia , Comunicação Parácrina , Animais , Comportamento Animal/fisiologia , Paralisia Cerebral/etiologia , Modelos Animais de Doenças , Feminino , Humanos , Gravidez , Coelhos
5.
Transplantation ; 89(6): 639-43, 2010 Mar 27.
Artigo em Inglês | MEDLINE | ID: mdl-20075790

RESUMO

Publicly available program-specific data from the scientific registry of transplant recipients were used to determine the association between adult lung transplant center volume and 1-year recipient mortality from 2000 to 2007. We found a significant inverse association between the center volume of adult lung transplants and 1-year recipient mortality that is growing more pronounced over time. We conclude that procedure volume is an increasingly important determinant of lung transplant center volume and that policies that improve the performance of low-volume centers or reduce the number of patients who use such centers may be warranted.


Assuntos
Hospitais/estatística & dados numéricos , Transplante de Pulmão/estatística & dados numéricos , Transplante de Pulmão/tendências , Avaliação de Processos e Resultados em Cuidados de Saúde/tendências , Adulto , Competência Clínica , Regulamentação Governamental , Política de Saúde , Humanos , Modelos Logísticos , Transplante de Pulmão/legislação & jurisprudência , Transplante de Pulmão/mortalidade , Avaliação de Processos e Resultados em Cuidados de Saúde/legislação & jurisprudência , Modelos de Riscos Proporcionais , Sistema de Registros , Estudos Retrospectivos , Medição de Risco , Fatores de Tempo , Resultado do Tratamento , Estados Unidos/epidemiologia , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...